Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 3b SEQUENCE Trial

被引：0

作者：

Peyrin-Biroulet, L. ^{[1
]}

Bossuyt, P. ^{[2
]}

Regueiro, M. ^{[3
]}

Schreiber, S. ^{[4
]}

Gecse, K. ^{[5
]}

Irving, P. ^{[6
]}

D'Haens, G. ^{[5
]}

Cao, Q. ^{[7
]}

Neimark, E. ^{[8
]}

Huang, X. ^{[9
]}

Anschutz, T. ^{[8
]}

Kligys, K. ^{[10
]}

O'Brien, D. ^{[10
]}

Panaccione, R. ^{[11
]}

机构：

[1] Univ Hosp Nancy Brabois, Dept Gastroenterol, Vandoeuvre Les Nancy, France

[2] Imelda Gen Hosp, Imelda GI Clin Res Ctr, Dept Gastroenterol, Bonheiden, Belgium

[3] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA

[4] Univ Kiel, Dept Med 1, Univ Hosp Schleswig Holstein, Kiel, Germany

[5] Amsterdam Univ Med Ctr, Dept Gastroenterol & Hepatol, Locat AMC, Amsterdam, Netherlands

[6] Guys & St Thomas NHS Fdn Trust, Gastroenterol Guys & St Thomas Hosp, London, England

[7] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gastroenterol, Coll Med, Hangzhou, Peoples R China

[8] AbbVie, Clin Dev, N Chicago, IL 60064 USA

[9] AbbVie, Stat, N Chicago, IL 60064 USA

[10] AbbVie, Med Affairs, N Chicago, IL 60064 USA

[11] Univ Calgary, Div Gastroenterol & Hepatol, Inflammatory Bowel Dis Unit, Calgary, AB, Canada

来源：

JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP10

引用

页码：I90 / I91

页数：2

共 50 条

[1] Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn's Disease: Results From the Phase 3B SEQUENCE Trial
Peyrin-Biroulet, Laurent
Chapman, Casey
Colombel, Jean-Frederic
Caprioli, Flavio
D'Haens, Geert
Ferrante, Marc
Schreiber, Stefan
Atreya, Raja
Danese, Silvio
Lindsay, James O.
Bossuyt, Peter
Siegmund, Britta
Irving, Peter
Panaccione, Remo
Neimark, Ezequiel
Wallace, Kori
Anschutz, Toni
Kligys, Kristina
Duan, W. Rachel
Pivorunas, Valerie
Huang, Xiu
Berg, Sofie
Shu, Lei
Dubinsky, Marla C.
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S1 - S1
[2] Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn's Disease: Results From the Phase 3b SEQUENCE Trial
Dubinsky, M. C.
D'Haens, G.
Atreya, R.
Abraham, B.
Armuzzi, A.
Arguelles-Arias, F.
Lindsay, J. O.
Patel, K.
Neimark, E.
Huang, X.
Anschutz, T.
van Haaren, S.
O'Brien, D.
Ferrante, M.
[J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I65 - I66
[3] Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
Peyrin-Biroulet, Laurent
Chapman, J. Casey
Colombel, Jean-Frederic
Caprioli, Flavio
D'Haens, Geert
Ferrante, Marc
Schreiber, Stefan
Atreya, Raja
Danese, Silvio
Lindsay, James O.
Bossuyt, Peter
Siegmund, Britta
Irving, Peter M.
Panaccione, Remo
Cao, Qian
Neimark, Ezequiel
Wallace, Kori
Anschutz, Toni
Kligys, Kristina
Duan, W. Rachel
Pivorunas, Valerie
Huang, Xiu
Berg, Sofie
Shu, Lei
Dubinsky, Marla
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (03): : 213 - 223
[4] Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
Bossuyt, Peter
Ferrante, Marc
Baert, Filip
Danese, Silvio
Feagan, Brian
Loftus, Edward V.
Panes, Julian
Peyrin-Biroulet, Laurent
Ran, Zhihua
Armuzzi, Alessandro
D'Haens, Geert
Song, Alexandra
Neimark, Ezequiel
Liao, Xiaomei
Zhou, Qian
Berg, Sofie
Wallace, Kori
Panaccione, Remo
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S358
[5] Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Bossuyt, P.
Ferrante, M.
Baert, F.
Danese, S.
Feagan, B. G.
Loftus, E. V., Jr.
Panes, J.
Peyrin-Biroulet, L.
Ran, Z.
Armuzzi, A.
D'Haens, G. R.
Song, A.
Neimark, E.
Liao, X.
Zhou, Q.
Berg, S.
Wallace, K.
Panaccione, R.
[J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S033 - S034
[6] Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn's Disease: Post hoc results from the phase 3b SEQUENCE trial
Raine, T.
Danese, S.
Schreiber, S.
Gao, X.
Hanauer, S.
Torres, J.
Kligys, K.
Huang, X.
Neimark, E.
Anschutz, T.
Crowley, J.
Cross, R. K.
[J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I189 - I189
[7] Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Schreiber, S. W.
Ferrante, M.
Panaccione, R.
Colombel, J. F.
Hisamatsu, T.
Lim, A.
Lindsay, J. O.
Rubin, D. T.
Sandborn, W. J.
Neimark, E.
Song, A. P.
Liao, X.
Feng, T.
Berg, S.
Wallace, K.
D'Haens, G. R.
[J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S026 - S027
[8] Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
Schreiber, Stefan
Ferrante, Marc
Panaccione, Remo
Colombel, Jean-Frederic
Hisamatsu, Tadakazu
Lim, Allen
Lindsay, James
Rubin, David T.
Sandborn, William
Neimark, Ezequiel
Song, Alexandra
Liao, Xiaomei
Feng, Tian
Berg, Sofie
Wallace, Kori
D'Haens, Geert
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S314 - S315
[9] Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease
Tuskey, Anne
Behm, Brian W.
[J]. CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 173 - 179
[10] Patients with moderate to severe Crohn's Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials
Ferrante, M.
Cao, Q.
Fujii, T.
Rausch, A.
Neimark, E.
Song, A.
Wallace, K.
Kligys, K.
Zhou, Q.
Kalabic, J.
Feagan, B. G.
[J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I027 - I028

← 1 2 3 4 5 →